Abstract
Lung cancer (LC) poses a public health problem owing to its high incidence and mortality, currently ranking as the deadliest cancer worldwide. With the aim of reducing mortality, the U.S. National Lung Screening Trial (NLST) was undertaken and revealed a reduction in LC mortality with the annual performance of low-dose computed tomography compared with chest radiography.1 This resulted in the implementation of screening nationwide. The Dutch-Belgian Randomized Lung Cancer Screening Trial (Nederlands–Leuvens Longkanker Screenings Onderzoek [NELSON]),2 the largest in Europe, also revealed a reduction in LC mortality after the introduction of low-dose computed tomography, but, unlike the U.S.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
